AQUESTIVE THERAPEUTICS
5.0900
20-九月-24 15:59:59
15 分钟延时
股票
-0.1100
-2.12%
今日范围
5.0550 - 5.2900
ISIN
N/A
来源
NASDAQ
-
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
09 9月 2024 08:15:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
22 8月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
06 8月 2024 16:22:19 条件 Nasdaq GlobeNewswire
-
25 7月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
23 7月 2024 08:00:01 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
27 6月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
25 6月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
18 6月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
03 6月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
28 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
09 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07 5月 2024 16:19:11 条件 Nasdaq GlobeNewswire
-
25 4月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
12 4月 2024 16:01:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
01 4月 2024 08:00:00 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
25 3月 2024 08:00:25 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
19 3月 2024 21:49:43 条件 Nasdaq GlobeNewswire
-
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
19 3月 2024 16:01:00 条件 Nasdaq GlobeNewswire
- <<
- <
- 1
- >